News
18h
TAG24 on MSNPeople with asthma warned against relying just on blue inhalersBlue reliever inhalers act quickly to treat symptoms and attacks, and people need to carry them for if their asthma flares up.However, a new warning from the regulator, the UK's Medicines and ...
Discover how African American families are navigating asthma care amid alarming health disparities, with actionable ...
Ariana Boyle, 7, has been hospitalised her more than 50 times due to her severe brittle asthma - but a last-resort treatment ...
Researchers have identified a compound that could block certain life-threatening and hard-to-treat allergic reactions.
Asthma is a chronic condition which leads to the airways to constrict and makes breathing difficult. Asthma has no cure, although medication can help manage symptoms. Asthma can be diagnosed and ...
Blue Cross is requiring at-home injection for severe asthma drugs in five states, raising concerns among doctors and patients ...
13h
Verywell Health on MSNDupixent: The First FDA-Approved Biologic Drug to Treat Uncontrolled COPDLast year, the FDA approved the biologic drug Dupixent to treat uncontrolled eosinophilic COPD. The approval marked a step ...
A new study from researchers at New York University and the University of Chicago offers a promising answer. The team, led by Dr. Jeffrey Hubbell and published in Science Translational Medicine, has ...
1d
Jacobin on MSNThe Insurer Making It Harder to Get Vital Asthma MedicineHealth insurer Blue Cross Blue Shield just adopted a policy that will force many people with serious asthma and allergy ...
5d
News-Medical.Net on MSNPatients with asthma reminded of the increased risk of severe asthma attacks from overusing blue inhalersThis reminder follows updates to product information and the National Institute for Health and Care Excellence (NICE) ...
Irritable bowel syndrome, chronic itching, asthma and migraine are in many cases hard-to-treat conditions. They have in common that they are triggered by an excessive immune response -- which in ...
New Phase II data demonstrate amlitelimab’s efficacy in heterogeneous inflammatory asthma, as lunsekimig and itepekimab ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results